The Patent Finder

Zymeworks BC Inc.

49 patents currently held · Updated Nov 22, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Zymeworks Inc. (to 2022)

0
Ending by 2030
Mar 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 23, 2027
    The maintenance fee for Multivalent Heteromultimer Scaffold Design and Constructs (US 10,358,479) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
  • 1 fee due Mar 17, 2027
    The maintenance fee for Cytotoxic and anti-mitotic compounds, and methods of using the same (US 10,414,822) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
  • 2 fees due Apr 22 to 29, 2027 · next Apr 22
  • 1 fee due Jun 17, 2027
    The maintenance fee for Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells (US 10,508,154) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
  • 1 fee due Sep 29, 2027
    The maintenance fee for Antibodies with enhanced or suppressed effector function (US 9,296,815) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
  • 2 fees due Oct 23, 2027

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,499,605Multivalent Heteromultimer Scaffold Design and Constructs
In force
 · High confidence
In forceHigh confidence
US 10,155,803Multivalent Heteromultimer Scaffold Design and Constructs
In force
 · High confidence
In forceHigh confidence
US 10,711,051Multivalent Heteromultimer Scaffold Design and Constructs
In force
 · High confidence
In forceHigh confidence
US 10,875,931Stable heterodimeric antibody design with mutations in the Fc domain
In force
 · USPTO record
In forceUSPTO record
US 9,296,815Antibodies with enhanced or suppressed effector function
In force
 · USPTO record
In forceUSPTO record
US 10,457,742Stable heterodimeric antibody design with mutations in the Fc domain
In force
 · USPTO record
In forceUSPTO record
US 10,508,154Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
In force
 · USPTO record
In forceUSPTO record
US 9,388,231Multivalent Heteromultimer Scaffold Design and Constructs
In force
 · High confidence
In forceHigh confidence
US 10,358,479Multivalent Heteromultimer Scaffold Design and Constructs
In force
 · High confidence
In forceHigh confidence
US 9,771,573Methods of Quantitating Heavy and Light Chain Polypeptide Pairs
In force
 · High confidence
In forceHigh confidence
10 of 49 patents shown.
Pro members see all 49.
Pro members: see all 49 patents
Also on record, not counted in the 49: 2 patents in force now held by others · 6 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

17 pending · 1 abandoned · 8 no status recorded

Showing 1 to 10 of 26, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/247,831Antibody-Drug Conjugates Targeting Folate Receptor Alpha and Methods of UseJun 24, 2025Pending
19/173,694Apr 8, 2025No status recorded
19/172,273Apr 7, 2025No status recorded
19/093,924ANTI-NAPI2B Antibodies and Methods of UseMar 28, 2025Pending
19/091,242Mar 26, 2025No status recorded
19/033,344Jan 21, 2025No status recorded
19/025,701Jan 16, 2025No status recorded
18/988,332Bispecific Antigen Binding Constructs Targeting HER2Dec 19, 2024Pending
18/932,013Oct 30, 2024No status recorded
18/886,501Sep 16, 2024No status recorded
10 of 26 applications shown.
Pro members see all 26 published applications.
Pro members: see all 26 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited